Self‐Promoted Targeting Delivery of Nanodrug Through Chemotherapeutic Upregulation of CD47 for Triple Negative Breast Cancer Therapy
Q Liu, X Chen, Y Jiang, M Yan, B Yu… - Advanced Functional …, 2024 - Wiley Online Library
The high heterogeneity of receptor expression and varied chemotherapeutic sensitivity
seriously compromise the therapeutic outcome of triple‐negative breast cancer (TNBC) …
seriously compromise the therapeutic outcome of triple‐negative breast cancer (TNBC) …
The Remarkable Anti-Breast Cancer Efficacy and Anti-Metastasis by Multifunctional Nanoparticles Co-Loading Squamocin, R848 and IR 780
X Wang, X Liu, Y Guo, T Gong, W Lu… - International Journal …, 2024 - Taylor & Francis
Background Breast cancer is a heterogeneous disease globally accounting for
approximately 1 million new cases annually. Chemotherapy remains the main therapeutic …
approximately 1 million new cases annually. Chemotherapy remains the main therapeutic …
[HTML][HTML] Hijacking 5-Fluorouracil Chemoresistance in Triple Negative Breast Cancer via microRNAs-Loaded Chitosan Nanoparticles
Chemotherapy is still the mainstay of treatment for triple-negative breast cancer (TNBC)
patients. Yet only 20% of TNBC patients show a pathologic complete response (pCR) after …
patients. Yet only 20% of TNBC patients show a pathologic complete response (pCR) after …
USP10 promotes the progression of triple-negative breast cancer by enhancing the stability of TCF4 protein
J Yang, Y Lu, H Su, Y Xiao, Q Pan, F Su… - Biochemical …, 2023 - Elsevier
Investigating the role of ubiquitin-specific peptidase 10 (USP10) in triple-negative breast
cancer (TNBC). Analyzed USP10 expression levels in tumors using public databases …
cancer (TNBC). Analyzed USP10 expression levels in tumors using public databases …
[HTML][HTML] Androgen and Estrogen β Receptor Expression Enhances Efficacy of Antihormonal Treatments in Triple-Negative Breast Cancer Cell Lines
B Crespo, JC Illera, G Silvan, P Lopez-Plaza… - International Journal of …, 2024 - mdpi.com
The triple-negative breast cancer (TNBC) subtype is characterized by the lack of expression
of ERα (estrogen receptor α), PR (progesterone receptor) and no overexpression of HER-2 …
of ERα (estrogen receptor α), PR (progesterone receptor) and no overexpression of HER-2 …
[HTML][HTML] Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced …
A Ilari, V Cogliati, N Sherif, E Grassilli, D Ramazzotti… - Biomedicines, 2024 - mdpi.com
A group of 27 patients diagnosed with metastatic triple-negative breast cancer (mTNBC) was
randomly distributed into two groups and underwent different lines of metronomic treatment …
randomly distributed into two groups and underwent different lines of metronomic treatment …
[HTML][HTML] Role of ICAM-1 in triple-negative breast cancer
Y Zhang, J Fan, X Wang, Z Wu, W Ma, B Ma - Open Medicine, 2024 - degruyter.com
Abstract Intercellular adhesion molecule-1 (ICAM-1) is related to the occurrence and
development of a variety of tumors. However, the role of ICAM-1 in the regulation of growth …
development of a variety of tumors. However, the role of ICAM-1 in the regulation of growth …
Exploring the Pharmacological Action Mechanism of Chamomile Essential Oil on the Treatment of Breast Cancer Based on Network Pharmacology
G Maitisha, J Zhou, Y Zhao, G Liu, Y Zhao, Y Zheng… - 2024 - researchsquare.com
Background Chamomile essential oil (CEO) can be beneficial in cancer therapy. The aim of
the current research is to explore the underlying mechanism of CEO for breast cancer …
the current research is to explore the underlying mechanism of CEO for breast cancer …